Understanding and minimizing late thrombosis of drug-eluting stents
Mark G. Rabbat, MD
Department of Internal Medicine, Cleveland Clinic
Anthony A. Bavry, MD, MPH
Department of Cardiovascular Medicine, Cleveland Clinic
Deepak L. Bhatt, MD
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Associate Director, Cleveland Clinic Cardiovascular Coordinating Center; Staff, Cardiac, Peripheral, and Carotid Intervention, Department of Cardiovascular Medicine, Cleveland Clinic
Stephen G. Ellis, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Head, Section of Invasive Cardiology, Department of Cardiovascular Medicine, Cleveland Clinic
Address: Stephen G. Ellis, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: email@example.com
Dr. Bavry has received honoraria from Genesis.
Dr. Bhatt has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering-Plough, and The Medicines Company.
Dr. Ellis has served as a consultant to Cordis, Boston Scientific, and Abbott, and receives research support from Cordis and Medtronic.
ABSTRACTAlthough the safety profiles of drug-eluting stents are similar to those of bare metal stents in the short term, concern has arisen about their potential for late thrombosis (occurring > 30 days after implantation). Stent thrombosis is rare but potentially devastating and can result in ST-segment elevation myocardial infarction or death. The aim of this article is to review the incidence, predictors, pathology, and prevention of late thrombosis of drug-eluting stents.